The Clinical Biospecimen and Research Core

临床生物样本和研究核心

基本信息

批准号：
10443135
负责人：
Julian Abrams
金额：
$ 23.82万
依托单位：
COLUMBIA UNIVERSITY HEALTH SCIENCES
依托单位国家：
美国
项目类别：
财政年份：
2022
资助国家：
美国
起止时间：
2022-04-30 至 2027-03-31
项目状态：
未结题

来源：
https://reporter.nih.gov/project-details/10443135
关键词：
Agreement Area Basic Science Bioinformatics Biometry Cancer Center Cell Culture Techniques Cell Nucleus Clinical Clinical Data Clinical Investigator Clinical Research Clinical effectiveness Collaborations Collection Consultations Custom Data Data Element Databases Digestive System Disorders Disease Educational workshop Electronic Health Record Ensure Epithelial Cells Feedback Fertilization Freezing Funding Goals Homeostasis Human Human Subject Research Image Immunologic Monitoring Infrastructure Interdisciplinary Study Leadership Link Liver diseases Longevity Mission Modeling Organ Organoids Patient Selection Patients Quality Control RNA Records Research Research Design Research Personnel Research Support Resources Sampling Science Scientist Services Small Nuclear RNA Specimen Structure Surveys Tissue Microarray Tissues Training Training and Education Translational Research United States National Institutes of Health Universities Work base biobank bioimaging cellular imaging cost effective data integration data management histopathological examination human subject innovation interest meetings member next generation novel operation patient population prevent programs repository single cell analysis symposium transcriptome sequencing translational study

项目摘要

PROJECT SUMMARY The overall goal of the Clinical Biospecimen and Research Core (CBRC) is to facilitate the conduct of clinical and translational studies in the Columbia University Digestive and Liver Disease Research Center (CU-DLDRC). The CBRC will provide research navigation services to its members to access extensive collections and storage of digestive organ biospecimens. This resource will also combine biospecimen collection and analysis with comprehensive clinical data elements. In concert with other CU-DLDRC Biomedical Cores, CBRC will enable state-of-the-art single cell, imaging and organoid modelling-based analyses of its biospecimens through multi- core workflows, thereby linking to the central theme “Epithelial Cells and Their Interactions in Digestive Homeostasis and Disease” in human relevant settings. Through collaborative agreements with established structures in the Cancer Center and Human Immune Monitoring cores, we will offer subsidized services such as single nucleus RNA-sequencing, tissue microarrays, expert histopathological examination and biostatistical support, thereby enhancing the capability of the CU-DLDRC to conduct impactful translational research. Collaborative translational research and cross-fertilization between clinical and basic investigators in the CU- DLDRC will be fertilized through a central infrastructure and consultative services for clinical research design and application under the umbrella of organ-specific clinical-basic teams. The organ-specific clinical-basic teams will support the analysis of CBRC-provided biospecimens in the CU-DLDRC biomedical cores through combined clinical and basic expertise and dialogue, and vice versa, will bring novel basic research concepts from bench to beside. The CBRC will led by two highly qualified NIH-funded clinical investigators, Dr. Julian Abrams (Director) and Dr. Elizabeth Verna (Associate Director). The following Specific Aims will maximize benefits and added value to CU-DLDRC members and contribute to the mission of the CU-DLDRC: To provide comprehensive biobanking of digestive organ biospecimens with linked clinical data (Aim 1); to enable state-of-the-art translational analyses of clinical samples (Aim 2); and to provide tailored human subjects research training, education, and biostatistical support (Aim 3). According to user surveys, 96% of CU-DLDRC researchers plan to utilize CBRC services. In conclusion, the CBRC will provide a crucial interface between clinical and basic CU-DLDRC investigators that does not exist in this form at Columbia and promote high quality collaborative translational research through access to a wealth of biospecimens. Through these services, the CBRC will provide major benefits to basic and clinical CU-DLDRC researchers alike.

项目概要临床生物样本和研究核心 (CBRC) 的总体目标是促进临床生物样本和研究核心的开展以及哥伦比亚大学消化和肝脏疾病研究中心 (CU-DLDRC) 的转化研究。银监会将为其会员提供研究导航服务，以访问广泛的馆藏和存储该资源还将生物样本收集和分析与消化器官生物样本结合起来。 CBRC 将与其他 CU-DLDRC 生物医学核心相结合，实现全面的临床数据元素。通过多种方式对其生物样本进行最先进的单细胞、成像和类器官建模分析核心工作流程，从而链接到中心主题“上皮细胞及其在消化中的相互作用” 通过与已建立的合作协议，在人类相关环境中实现“稳态与疾病”。癌症中心和人体免疫监测核心的结构，我们将提供补贴服务，例如单核 RNA 测序、组织微阵列、专家组织病理学检查和生物统计支持，从而增强 CU-DLDRC 开展有影响力的转化研究的能力。 CU 临床和基础研究人员之间的合作转化研究和交叉受精 DLDRC 将通过临床研究设计的中央基础设施和咨询服务得到充实并在器官特异性临床基础团队的保护下进行应用。将通过联合支持对 CU-DLDRC 生物医学核心中 CBRC 提供的生物样本进行分析临床和基础专业知识和对话，反之亦然，将带来新的基础研究概念从实验室到 CBRC 将由 NIH 资助的两名高素质临床研究人员 Julian Abrams 博士（主任）领导。和 Elizabeth Verna 博士（副主任）以下具体目标将实现效益和附加值最大化。向 CU-DLDRC 成员提供帮助，并为 CU-DLDRC 的使命做出贡献：提供全面的生物样本库消化器官生物样本与相关临床数据（目标 1），以实现最先进的转化分析；临床样本（目标 2）；并提供量身定制的人类受试者研究培训、教育和生物统计支持（目标 3）根据用户调查，96% 的 CU-DLDRC 研究人员计划使用 CBRC 服务。结论是，CBRC 将在临床和基础 CU-DLDRC 研究人员之间提供一个重要的接口，哥伦比亚大学不存在这种形式，并通过以下方式促进高质量的合作转化研究通过这些服务，银监会将为基础和医疗保健提供重大好处。临床 CU-DLDRC 研究人员等。